1.39
price up icon0.00%   0.00
pre-market  Pre-market:  1.40   0.01   +0.72%
loading
Opko Health Inc stock is traded at $1.39, with a volume of 1.83M. It is up +0.00% in the last 24 hours and up +2.96% over the past month. OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
See More
Previous Close:
$1.39
Open:
$1.39
24h Volume:
1.83M
Relative Volume:
0.53
Market Cap:
$1.04B
Revenue:
$581.12M
Net Income/Loss:
$-212.92M
P/E Ratio:
-5.0767
EPS:
-0.2738
Net Cash Flow:
$-174.22M
1W Performance:
+2.96%
1M Performance:
+2.96%
6M Performance:
+14.88%
1Y Performance:
+5.30%
1-Day Range:
Value
$1.38
$1.4068
1-Week Range:
Value
$1.32
$1.4087
52-Week Range:
Value
$0.9769
$1.73

Opko Health Inc Stock (OPK) Company Profile

Name
Name
Opko Health Inc
Name
Phone
305-575-4181
Name
Address
4400 BISCAYNE BLVD., MIAMI, FL
Name
Employee
2,275
Name
Twitter
Name
Next Earnings Date
2026-07-27
Name
Latest SEC Filings
Name
OPK's Discussions on Twitter

Compare OPK vs TMO, DHR, NTRA, IDXX, A

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
OPK icon
OPK
Opko Health Inc
1.39 1.04B 581.12M -212.92M -174.22M -0.2738
TMO icon
TMO
Thermo Fisher Scientific Inc
603.01 223.70B 45.20B 6.87B 6.75B 18.19
DHR icon
DHR
Danaher Corp
205.79 145.83B 24.78B 3.68B 5.29B 5.1743
NTRA icon
NTRA
Natera Inc
315.96 45.08B 2.50B -226.32M 71.51M -1.6412
IDXX icon
IDXX
Idexx Laboratories Inc
570.58 46.22B 4.45B 1.10B 1.06B 13.59
A icon
A
Agilent Technologies Inc
148.24 42.22B 7.23B 1.41B 1.09B 4.979

Opko Health Inc Stock (OPK) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-20-25 Initiated JP Morgan Neutral
Oct-31-25 Downgrade Jefferies Buy → Hold
Apr-25-25 Initiated JP Morgan Neutral
Jun-29-23 Upgrade Barrington Research Mkt Perform → Outperform
Dec-15-22 Initiated H.C. Wainwright Buy
Jan-24-22 Downgrade Barrington Research Outperform → Mkt Perform
Jun-21-21 Initiated Ladenburg Thalmann Buy
Nov-25-19 Initiated Piper Jaffray Overweight
Mar-02-18 Downgrade JP Morgan Neutral → Underweight
Sep-14-17 Downgrade JP Morgan Overweight → Neutral
Jun-21-16 Reiterated Standpoint Research Buy
Jun-03-16 Initiated Standpoint Research Buy
Mar-31-16 Reiterated Barrington Research Outperform
Oct-16-15 Initiated JP Morgan Overweight
Sep-11-15 Downgrade Jefferies Buy → Hold
Mar-03-15 Downgrade Oppenheimer Outperform → Perform
May-12-14 Reiterated Oppenheimer Outperform
Mar-14-14 Initiated Oppenheimer Outperform
Nov-13-13 Reiterated Ladenburg Thalmann Buy
May-30-13 Reiterated Ladenburg Thalmann Buy
Oct-22-12 Initiated Barrington Research Outperform
Dec-01-11 Reiterated Ladenburg Thalmann Buy
Jul-14-11 Initiated Ladenburg Thalmann Buy
View All

Opko Health Inc Stock (OPK) Latest News

pulisher
Aug 11, 2026

Opko Health, Inc. (OPK) Stock Analysis: Exploring A 214.75% Potential Upside - DirectorsTalk Interviews

Aug 11, 2026
pulisher
Aug 10, 2026

Does OPKO Health’s Sharply Narrowed Q2 Loss Reset the Bull Case for OPKO Health (OPK)? - Sahm

Aug 10, 2026
pulisher
Aug 10, 2026

OPKO Health Inc (OPK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Aug 10, 2026
pulisher
Aug 07, 2026

Opko Health | SCHEDULE 13D: Others - Moomoo

Aug 07, 2026
pulisher
Aug 04, 2026

OPKO Health: Mazdutide And MDX-2201 Could Change Everything (NASDAQ:OPK) - Seeking Alpha

Aug 04, 2026
pulisher
Aug 04, 2026

OPKO Health (OPK) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Aug 04, 2026
pulisher
Aug 03, 2026

OPKO Health invests $5 million in Cocrystal Pharma By Investing.com - Investing.com South Africa

Aug 03, 2026
pulisher
Aug 03, 2026

Weekly Recap: Q2 2026 financial results and MDX trial timelines - tradingview.com

Aug 03, 2026
pulisher
Aug 03, 2026

Cocrystal Pharma Raises $5 Million in Private Placement With OPKO Health at $0.9134/Share - tradingview.com

Aug 03, 2026
pulisher
Aug 03, 2026

Cocrystal Pharma (NASDAQ: COCP) secures $5M investment from OPKO Health - Stock Titan

Aug 03, 2026
pulisher
Aug 03, 2026

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health - GlobeNewswire

Aug 03, 2026
pulisher
Aug 03, 2026

OPKO Buys 5.47M Cocrystal Shares Ahead of Late-2026 Norovirus Data - Stock Titan

Aug 03, 2026
pulisher
Aug 02, 2026

Opko Health Earnings Call Highlights Pipeline, Profit Pivot - The Globe and Mail

Aug 02, 2026
pulisher
Aug 01, 2026

Opko Health Launches Early MASH Trial That Could Shape Its Next Growth Chapter - The Globe and Mail

Aug 01, 2026
pulisher
Aug 01, 2026

OPKO Health: A Hold As Progress Continues (NASDAQ:OPK) - Seeking Alpha

Aug 01, 2026
pulisher
Jul 31, 2026

Opko Health, Inc. Revenue Breakdown – NASDAQ:OPK - tradingview.com

Jul 31, 2026
pulisher
Jul 31, 2026

OPKO Health (OPK) Is Up 14.1% After Narrower Q2 Loss and New 2026 Revenue Guidance – Has The Bull Case Changed? - simplywall.st

Jul 31, 2026
pulisher
Jul 30, 2026

Earnings Beat: OPKO Health, Inc. (NASDAQ:OPK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Moomoo

Jul 30, 2026
pulisher
Jul 30, 2026

Cocrystal Pharma, Inc. announced that it has received $5 million in funding from OPKO Health, Inc. - marketscreener.com

Jul 30, 2026
pulisher
Jul 29, 2026

OPKO Health Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

Jul 29, 2026
pulisher
Jul 29, 2026

Analysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), Atea Pharmaceuticals (AVIR) - The Globe and Mail

Jul 29, 2026
pulisher
Jul 29, 2026

Analysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), AbbVie (ABBV) - The Globe and Mail

Jul 29, 2026
pulisher
Jul 28, 2026

Crude Oil Down Over 5%; Boeing Shares Rise After Q2 Results - Benzinga

Jul 28, 2026
pulisher
Jul 28, 2026

OPKO Health (NASDAQ:OPK) Shares Gap Up Following Strong Earnings - MarketBeat

Jul 28, 2026
pulisher
Jul 28, 2026

Why Is OPKO Health (NASDAQ:OPK) Stock Drawing Fresh Market Interest Today? - Kalkine Media

Jul 28, 2026
pulisher
Jul 28, 2026

Piper Sandler Maintains Opko Health(OPK.US) With Buy Rating, Maintains Target Price $3 - Moomoo

Jul 28, 2026
pulisher
Jul 28, 2026

OPK Looks 19.0% Overvalued on GF Value™ - GuruFocus

Jul 28, 2026
pulisher
Jul 28, 2026

Opko Health, Inc. (OPK) Stock Analysis: Exploring a 252.82% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews

Jul 28, 2026
pulisher
Jul 28, 2026

Opko Health | 4: Statement of changes in beneficial ownership of securities-Officer Rubin Steven D - Moomoo

Jul 28, 2026
pulisher
Jul 27, 2026

OPKO Health, Inc. 2026 Q2 10-Q Report: Financial Statements, Risk Factors, and Management Discussion - Minichart

Jul 27, 2026
pulisher
Jul 27, 2026

OPK Looks 17.9% Overvalued on GF Value™ - GuruFocus

Jul 27, 2026
pulisher
Jul 27, 2026

OPKO Health Q2 2026 Results: Key Pipeline Advances, Rayaldee China Expansion, and Improved Financial Performance – Minichart - Minichart

Jul 27, 2026
pulisher
Jul 27, 2026

OPKO Health (NASDAQ:OPK) Shares Rise After Q2 Earnings Exceed Forecasts; Nicoya Agreement Lifts After-Hours Gains - TechStock²

Jul 27, 2026
pulisher
Jul 27, 2026

Earnings call transcript: OPKO Health posts smaller Q2 loss, shares rise in 2026 - Investing.com Canada

Jul 27, 2026
pulisher
Jul 27, 2026

OPK: Q2 2026 delivered higher revenue, improved margins, and raised full-year guidance amid pipeline advances - TradingView

Jul 27, 2026
pulisher
Jul 27, 2026

OPKO Health Q2 Earnings Call Highlights - MarketBeat

Jul 27, 2026
pulisher
Jul 27, 2026

Compared to Estimates, OPKO Health (OPK) Q2 Earnings: A Look at Key Metrics - Yahoo Finance

Jul 27, 2026
pulisher
Jul 27, 2026

OPK: Profitability improved and revenue grew in Q2 2026, with guidance raised for the full year - TradingView

Jul 27, 2026
pulisher
Jul 27, 2026

OPK Looks 17.0% Overvalued on GF Value™ - GuruFocus

Jul 27, 2026
pulisher
Jul 27, 2026

OPKO Health (OPK) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance

Jul 27, 2026
pulisher
Jul 27, 2026

12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga

Jul 27, 2026
pulisher
Jul 27, 2026

OPKO Health Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Jul 27, 2026
pulisher
Jul 27, 2026

OPKO Health Q2 EPS beats estimates as sales rise 4.3% to $163.5 million - scanx.trade

Jul 27, 2026
pulisher
Jul 27, 2026

OPKO Health (NASDAQ:OPK) Issues Earnings Results - MarketBeat

Jul 27, 2026
pulisher
Jul 27, 2026

OPKO HEALTH ($OPK) Releases Q2 2026 Earnings, Stock Rises - Quiver Quantitative

Jul 27, 2026
pulisher
Jul 27, 2026

OPKO HEALTH, INC. Q2 2026: Revenue $163.6M, EPS $(0.01) — 10-Q Summary - TradingView

Jul 27, 2026
pulisher
Jul 27, 2026

OPKO Health: Q2 Earnings Snapshot - Yahoo Finance

Jul 27, 2026
pulisher
Jul 27, 2026

(OPK) OPKO Health, Inc. Expects Q3 Revenue Range $131.0M$142.0M - marketscreener.com

Jul 27, 2026
pulisher
Jul 27, 2026

OPKO Health reports Q2 2026 revenue $163.5M, operating loss narrows to $7.0M, net loss $8.4M - TradingView

Jul 27, 2026
pulisher
Jul 27, 2026

OPKO Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Jul 27, 2026
pulisher
Jul 27, 2026

OPK: Q2 2026 revenue rose and losses narrowed, with clinical and partnership progress highlighted - tradingview.com

Jul 27, 2026

Opko Health Inc Stock (OPK) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Opko Health Inc Stock (OPK) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
FROST PHILLIP MD ET AL
CEO & Chairman
Nov 21 '25
Buy
1.33
580,000
768,807
216,706,448
FROST PHILLIP MD ET AL
CEO & Chairman
Nov 20 '25
Buy
1.33
580,000
771,328
216,126,448
FROST PHILLIP MD ET AL
CEO & Chairman
Nov 19 '25
Buy
1.31
580,000
759,115
215,546,448
FROST PHILLIP MD ET AL
CEO & Chairman
Nov 18 '25
Buy
1.27
533,300
678,906
214,966,448
FROST PHILLIP MD ET AL
CEO & Chairman
Oct 31 '25
Buy
1.42
150,000
213,435
214,386,448
DGX DGX
$237.77
price up icon 0.11%
MTD MTD
$1,438.53
price up icon 0.09%
$192.91
price up icon 0.04%
IQV IQV
$241.71
price down icon 0.87%
WAT WAT
$416.15
price up icon 0.28%
A A
$148.24
price down icon 0.84%
Cap:     |  Volume (24h):